Pyoderma gangrenosum - Pioderma Gangrenosum
Pioderma Gangrenosum (Pyoderma gangrenosum) adalah penyakit kulit inflamasi langka yang ditandai dengan pustula atau nodul yang menyakitkan dan berkembang menjadi bisul yang semakin besar. Pioderma Gangrenosum (Pyoderma gangrenosum) tidak menular. Perawatan dapat meliputi kortikosteroid, siklosporin, atau berbagai antibodi monoklonal. Meskipun penyakit ini dapat menyerang orang dari segala usia, paling sering terjadi pada individu berusia 40‑50 tahun.
☆ AI Dermatology — Free Service
Pada hasil Stiftung Warentest tahun 2022 dari Jerman, kepuasan konsumen terhadap ModelDerm hanya sedikit lebih rendah dibandingkan dengan konsultasi telemedis berbayar.
Pada hasil Stiftung Warentest tahun 2022 dari Jerman, kepuasan konsumen terhadap ModelDerm hanya sedikit lebih rendah dibandingkan dengan konsultasi telemedis berbayar.
Pada kaki penderita kolitis ulserativa.
relevance score : -100.0%
ReferencesPyoderma gangrenosum adalah kondisi kulit langka yang menimbulkan bisul menyakitkan dengan tepi berwarna merah atau keunguan. Penyakit ini diklasifikasikan sebagai penyakit inflamasi dan termasuk dalam kelompok dermatosis neutrofil. Penyebab Pyoderma gangrenosum sangat kompleks, melibatkan gangguan imunitas bawaan dan adaptif pada individu yang memiliki kerentanan genetik. Baru-baru ini, para peneliti memfokuskan perhatian pada folikel rambut sebagai titik awal potensial penyakit ini.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum adalah kondisi kulit langka yang menyebabkan bisul sangat menyakitkan. Meskipun penyebabnya belum sepenuhnya dipahami, diketahui bahwa penyakit ini melibatkan peningkatan aktivitas sel‑sel kekebalan tertentu. Pengobatan penyakit ini masih menantang. Tersedia berbagai obat yang menekan atau mengubah aktivitas sistem kekebalan. Selain itu, perawatan luka dan penanganan nyeri juga menjadi fokus. Kortikosteroid dan siklosporin sering menjadi pilihan pertama, namun belakangan ini semakin banyak penelitian mengenai terapi biologis, seperti penghambat TNF‑α. Obat‑obatan biologis tersebut semakin disukai, terutama pada pasien dengan kondisi peradangan lain, dan dapat digunakan pada tahap awal penyakit.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
